Edge Therapeutics, Inc. 4
4 · Edge Therapeutics, Inc. · Filed Oct 8, 2015
Insider Transaction Report
Form 4
Macdonald R. Loch
DirectorChief Scientific Officer
Transactions
- Conversion
Common Stock
2015-10-06+18,274→ 566,480 total - Conversion
Series A Convertible Preferred Stock
2015-10-06−25,000→ 0 total→ Common Stock (18,274 underlying) - Other
Common Stock
2015-10-06$7.90/sh+194$1,533→ 570,602 total - Conversion
Series C-1 Convertible Preferred Stock
2015-10-06−5,373→ 0 total→ Common Stock (3,928 underlying) - Conversion
Common Stock
2015-10-06+3,928→ 570,408 total
Footnotes (2)
- [F1]The convertible preferred stock converted into the Issuer's common stock at a conversion ratio, as adjusted to give effect to the Issuer's 1-for-1.3681 reverse stock split effected on September 21, 2015, of one share of common stock for every 1.3681 shares of preferred stock immediately prior to the closing of the Issuer's initial public offering of common stock, and had no expiration date.
- [F2]The Reporting Person received a total of 194 shares of the Issuer's common stock which represented a payment-in-kind dividend on 5,373 shares of the Issuer's convertible preferred stock owned at the time of the dividend payment date.